

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-5 (canceled).

6. (currently amended) An isolated polynucleotide comprising ~~150 contiguous nucleotides a sequence~~ having at least about 90% sequence identity to ~~a sequence within nucleotides 1 to 11,407 nucleotides about 8021 to about 8371~~ of SEQ ID NO:1, ~~said polynucleotide having enhancer activity, wherein said 150 contiguous nucleotides are not depicted within SEQ ID NO:2 or SEQ ID NO:3 and said 150 contiguous nucleotides have~~ wherein said polynucleotide has prostate-specific enhancer activity.

7. (canceled)

8. (currently amended) An isolated polynucleotide comprising nucleotides about 8021 to about 8371 of SEQ ID NO:1, wherein said polynucleotide has prostate-specific enhancer activity.

9. (currently amended) An isolated polynucleotide according to of claim 8, wherein the polynucleotide comprises nucleotides about 7200 to about 8371 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

10. (currently amended I) An isolated polynucleotide according to ~~of~~ claim 8, wherein the polynucleotide comprises nucleotides about 6859 to about 8627 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

11. (currently amended) An isolated polynucleotide according to ~~of~~ claim 8, wherein the polynucleotide comprises nucleotides about 5976 to about 9620 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

12. (currently amended) An isolated polynucleotide according to ~~of~~ claim 8, wherein the polynucleotide comprises nucleotides about 1 to about 9765 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

13-30 (canceled)

31. (previously presented) An adenovirus vector for selective cytolysis of a prostate target cell comprising an adenovirus gene essential for replication under transcriptional control of a human glandular kallikrein transcription regulatory element (*hKLK2*-TRE), wherein said *hKLK2*-TRE comprises a promoter and nucleotides about 8021 to about 8371 of SEQ ID NO:1.

32. (previously presented) The adenovirus vector of claim 31, wherein said adenovirus gene essential for adenoviral replication is selected from the group consisting of E1A, E1B, E2 and E4.

33-83 (canceled)

84. (new) The adenovirus vector according to Claim 31 wherein said *hKLK2*-TRE comprises nucleotides about 7200 to about 8371 of SEQ ID NO:1.

85. (new) The adenovirus vector according to claim 84, wherein said adenovirus gene essential for adenoviral replication is selected from the group consisting of E1A, E1B, E2 and E4.

86. (new) The adenovirus vector according to Claim 31 wherein said *hKLK2*-TRE comprises nucleotides about 6859 to about 8627 of SEQ ID NO:1.

87. (new) The adenovirus vector according to claim 86, wherein said adenovirus gene essential for adenoviral replication is selected from the group consisting of E1A, E1B, E2 and E4.

88. (new) The adenovirus vector according to Claim 31 wherein said *hKLK2*-TRE comprises nucleotides about 5976 to about 9620 of SEQ ID NO:1.

89. (new) The adenovirus vector according to Claim 31 wherein said *hKLK2*-TRE comprises nucleotides about 1 to about 9765 of SEQ ID NO:1.